ReviewMolecular neurobiology2025
miR-132 and Its Exosomal Form in Alzheimer's Disease: Linking Epigenetic Regulation to Neurodegeneration.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by distinct neuropathological features, including amyloid-beta (Aβ) plaques, neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau, synaptic dysfunction, and chronic neuroinflammation. MicroRNAs (miRNAs), as critical post-transcriptional regulators, exert a profound influence on central nervous system (CNS) function and are increasingly implicated in the pathogenesis of AD. Among these, miR-132 stands out as a brain-enriched miRNA that is consistently downregulated in AD, affecting various aspects of the disease, from Aβ and tau pathologies to synaptic integrity and neuronal survival. Simultaneously, exosomes, nanoscale extracellular vesicles, play a crucial role in intercellular communication and are capable of transporting miRNAs across biological barriers such as the blood-brain barrier. This comprehensive review synthesizes the current understanding of miR-132's intrinsic roles in neuronal health and its dysregulation in AD, elucidates the mechanisms underlying exosome-mediated communication, and explores the complex interplay between exosomal miR-132 and AD pathology. Furthermore, we examine the significant role of epigenetic regulation in modulating miR-132 expression and its broader implications for neurodegeneration. By evaluating the diagnostic potential of miR-132 and its exosomal form as non-invasive biomarkers, as well as their promising therapeutic applications, this review underscores the multifaceted importance of miR-132 in AD. Challenges in current research, particularly with regard to the standardization of exosome isolation methods and the complexity of miRNA regulatory networks, are discussed, highlighting the need for future comprehensive studies to translate these findings into effective clinical strategies for AD management.
Indexed as
Identifiers
41298994What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.